Resources 
Product Resource
Learning
We Are Pleased to Announce: Global Commercial Licensing Rights for Jurkat E6.1, CHO-K1, and HEK293 Cell Lines Officially Secured.
ExploreArticles
Orphan Receptor GPR84: The "Invisible Switch" Linking Metabolism and Inflammation
GPR84 is an orphan GPCR primarily expressed in immune cells that responds to medium-chain fatty acids (MCFAs) and regulates inflammation and metabolism, emerging as a novel target for diseases such as ulcerative colitis (UC), fibrosis, and NASH. This article systematically interprets the biological functions, signaling pathways, and clinical progress of GPR84, while highlighting the validation data and advantages of ReqBio’s GPR84/CHO and GPR84/β-Arrestin/CHO cell models—providing reliable tools for your early-stage drug R&D.
Targeting C3aR: A New Chapter in the Complement System -A Key Target from Inflammatory Regulation to Cancer Immunotherapy
C3aR is a central receptor of the complement system. Through dual activation by C3a and the novel ligand TLQP-21, it regulates inflammatory and immune responses, emerging as a promising target for cancer immunotherapy. This article systematically interprets the biological functions, signaling pathways, and drug R&D progress of C3aR, while showcasing the C3aR/CHO and C3aR/β-Arrestin/CHO cell models developed by ReqBio. With proven validation data advantages, these models provide reliable tools for your early-stage drug development.
Targeting 5-HTR2: A Versatile Receptor from the Nervous System to Metabolic Diseases and Its Drug Screening Models
The 5-HTR2 family consists of key receptors in the serotonin signaling pathway, playing vital roles in neurological disorders, obesity, and cancer. This article provides a systematic interpretation of the biological functions, signal transduction mechanisms, and drug R&D progress for 5-HTR2A/2B/2C. We also showcase the series of cell models developed by Reqbio, offering high-efficiency screening tools for your early-stage drug discovery.
From Inflammation to Cancer: Biological Functions of the CCL2-CCR2 Axis and New Progress in Targeted Drug R&D
As our understanding of the tumor microenvironment deepens, targeting the CCL2-CCR2 axis is transitioning from concept to clinical reality. Whether you are developing small molecule inhibitors, neutralizing antibodies, or novel ADCs, reliable screening models are the cornerstone of success. Reqbio remains committed to focusing on frontier targets in GPCRs and immuno-oncology, providing high-quality biological reagents and cell models to empower global innovative drug discovery.
Unlocking the Dual Potential of ICOS: The Next Frontier in Immuno-Oncology and ICOS (CD278) Cell Model Solutions
With the deepening understanding of ICOS biology and the optimization of combination therapy strategies, this target holds great promise for the development of breakthrough therapeutics in the near future. Renkun Biotech remains committed to providing high-quality biological reagents and cell models to empower innovative drug discovery worldwide. Whether you are developing novel ICOS antibodies or exploring combination therapies, our tools are designed to accelerate your research from the lab to the clinic.
Focusing on the IL-17 Target: The "Golden Track" of Autoimmune Drug R&D and Essential Tool Models
ReqBio remains committed to the frontiers of immunotherapy, providing high-quality biological reagents and cell models to help global researchers conquer autoimmune diseases.
